Universitè Laval

Universite Claude Bernard – Lyon1

Ecole Normale Superieure De Lyon

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique-cnrs

Institut National De La Sante Et De La Recherche Medicale (inserm)

Centre National De La Recherche Scientifique

Hospices Civils De Lyon

Guy Boivin

Olivier Terrier

Manuel Rosa-Calatrava

Mario Andres Pizzorno

Julien Textoris

Sheng-Xiang Lin

Arezki Azzi

Mario Pizzorno

Julia Dubois

Marie-Eve Hamelin

Marie-Helene Cavanagh

Claire Nicolas De Lamballerie

Mario-Andres Pizzorno

Melanie Martin

Blandine Padey

Manuel Rosa-calatrava

The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

Combination of diltiazem and viral polymerase inhibitors

The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.

Diltiazem for use in the treatment of microbial infections

The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.

Attenuated virus strain and use thereof as a vaccine

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Antiviral compositions for treating the flu

3D protein modeling and virtual screening of commercially-available compounds were performed to identify new inhibitors of the herpesvirus DNA polymerase, a key enzyme in the viral replication cycle. Two compounds (Nos 2 and 9) were particularly active against HSV-1 and HSV-2 strains and one compound (No 3) inhibited specifically cytomegalovirus (CMV) strains (overall hit rate of 25%). Some of the tested compounds inhibited wild-type viruses and strains resistant to current antiviral agents. New chemical entity derivatives of compound 2 with binding potential to the DNA polymerase retained an excellent activity against HSV-1, HSV-2 and VZV like the parental compound, as well against strains resistant to current antiviral agents. These non-nucleosidic herpesvirus DNA polymerase inhibitors with in vitro activity against drug-resistant clinical isolates warrant further pre-clinical studies.

Compounds for the inhibition of herpes viruses

Growing community of inventors

CA

Guy Boivin